News stories about Enzo Biochem (NYSE:ENZ) have trended somewhat positive on Sunday, Accern Sentiment reports. Accern identifies negative and positive press coverage by monitoring more than twenty million news and blog sources. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Enzo Biochem earned a news impact score of 0.16 on Accern’s scale. Accern also assigned news headlines about the medical research company an impact score of 48.026768553652 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the next few days.
Separately, TheStreet lowered Enzo Biochem from a “b” rating to a “c+” rating in a research note on Wednesday, September 27th.
Enzo Biochem (ENZ) opened at $8.68 on Friday. Enzo Biochem has a one year low of $6.27 and a one year high of $12.04. The company has a market capitalization of $404.06, a P/E ratio of -217.00 and a beta of 0.87.
Enzo Biochem (NYSE:ENZ) last announced its quarterly earnings results on Thursday, December 7th. The medical research company reported ($0.01) EPS for the quarter, meeting analysts’ consensus estimates of ($0.01). Enzo Biochem had a negative return on equity of 1.89% and a negative net margin of 1.53%. The company had revenue of $27.68 million during the quarter, compared to analyst estimates of $27.51 million. equities analysts anticipate that Enzo Biochem will post -0.02 EPS for the current fiscal year.
In related news, CFO Barry W. Weiner sold 54,126 shares of the stock in a transaction that occurred on Wednesday, October 25th. The stock was sold at an average price of $10.11, for a total transaction of $547,213.86. Following the completion of the transaction, the chief financial officer now directly owns 1,423,367 shares of the company’s stock, valued at $14,390,240.37. The sale was disclosed in a filing with the SEC, which is available through this link. Also, EVP James Michael O’brien sold 22,866 shares of the stock in a transaction that occurred on Friday, October 27th. The shares were sold at an average price of $10.28, for a total value of $235,062.48. Following the transaction, the executive vice president now directly owns 34,886 shares of the company’s stock, valued at $358,628.08. The disclosure for this sale can be found here. Over the last three months, insiders have sold 191,398 shares of company stock valued at $1,925,292. 8.90% of the stock is owned by corporate insiders.
COPYRIGHT VIOLATION WARNING: This piece of content was published by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are viewing this piece of content on another domain, it was stolen and republished in violation of U.S. & international trademark and copyright legislation. The original version of this piece of content can be accessed at https://www.dispatchtribunal.com/2017/12/24/somewhat-positive-media-coverage-somewhat-unlikely-to-affect-enzo-biochem-enz-stock-price.html.
About Enzo Biochem
Enzo Biochem, Inc is a bioscience company focusing on delivering and applying technology capabilities to produce products and services. The Company’s segments include Enzo Clinical Labs, Enzo Life Sciences and Enzo Therapeutics. Enzo Clinical Labs is a clinical reference laboratory providing a range of clinical services to physicians, medical centers, other clinical labs and pharmaceutical companies.
Receive News & Ratings for Enzo Biochem Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enzo Biochem and related companies with MarketBeat.com's FREE daily email newsletter.